Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma
Berman, Zachary T. , Garza‐Ramos, Cynthia De la , Montazeri, Seyed Ali , Malone, Christopher D. , Sandow, Tyler, Gimenez, Juan , Young, Shamar, Fidelman, MD Nicholas, Pianka, Kurt, Sher, Alex, Vakil, Parmede , Wang, Melinda , Abounorinejad, Faraz, Johnson, Guy E. , Padia, Siddarth, Kim, Edward , Toskich, Beau B. , De la Garza-Ramos, Cynthia , Montazeri, S Ali , Fidelman, Nicholas , Pianka, Kurt T , Alamuri, Tharun , Chan, Shin Mei , Wang, Melinda , Abounorinejad, Faraz , Padia, Siddarth A , Kim, Edward , Toskich, Beau , Berman, Zachary T. , Malone, Christopher D , Sandow, Tyler Allan , Sher, Alex , Chan, Shin Mei , Som, Avik

Mayo Clinic

Radiology | May 5, 2026 | Volume: 319 | Issue: 2 | Pages: No page available

10.1148/radiol.251923 | PMID 42084516 Get It

Among patients with treatment-naive hepatocellular carcinoma, glass microsphere radiation segmentectomy before liver transplant achieved high rates of complete pathologic necrosis, which was positively associated with the number of optimized treatment parameter thresholds.
Coincident epithelial signals restrain commensal-specific CD8αβ + T cells in the intestine
Olsen, Tayla M., Verma, Sheenam, Makani, Venkata K K, Cameron, Benjamin, Gralen, Addison R, Johnson, Aaron J, Joglekar, Alok V, Byrd, Allyson L. , Harrison, Oliver J , Dufort, Matthew J. , Makani, Venkata Krishna Kanth , Cameron, Benjamin, Johnson, Aaron J. , Joglekar, Alok V. , Lacy‐Hulbert, Adam

Mayo Clinic

No container title available | May 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.29.720676 | PMID 42146659 Get It

Abstract The intestinal epithelium harbors a large population of microbiota-dependent CD8αβ + T cells whose antigen specificity and regulation are ill-defined. By identifying MHCIa-restricted TCRs and generating tetramers against the gut commensal Segmented Filamentous Bacteria, we demonstrate that a single commensal species drives a clonally expanded, antigen-specific CD8αβ + T cell within the intraepithelial lymphocyte compartment. Mechanistically, the intestinal epithelium coordinates coincident signals governing this population: peptide:MHC-dependent TCR engagement drives pIEL accumulation, while αvβ6-mediated TGFβ activation restraints effector cell differentiation. Perturbation of epithelial cell-mediated TGFβ activation diverts commensal-specific CD8 + T cells toward inflammatory differentiation states transcriptionally convergent with those observed in ulcerative colitis. The intestinal epithelium thus functions as a dual-signal organizer of commensal-specific CD8 + T cell responses, coupling differentiation to restraint through spatially coincident molecular cues.
Criterion and convergent validity of plasma biomarkers in early‐onset Alzheimer's disease: Initial findings from LEADS
Hammers, Dustin B., Polsinelli, Angelina, Eloyan, Ani, Taurone, Alexander, Thangarajah, Maryanne, Foroud, Tatiana, Gao, Sujuan, Beckett, Laurel, Joie, Renaud La, Touroutoglou, Alexandra, Vemuri, Prashanthi, Zetterberg, Henrik, Blennow, Kaj, Nemes, Sára , Костадинова, Ралица, Aisen, Paul, Nudelman, Kelly N., Kirby, Kala, Atri, Alireza, Clark, David, Day, Gregory S., Duara, Ranjan, Graff‐Radford, Neill R., Grant, Ian, Honig, Lawrence S., Johnson, Erik C. B., Jones, David T., Masdeu, Joseph C., Mendez, Mario F., Parand, Leila, Womack, Kyle, Musiek, Erik, Onyike, Chiadi U., Riddle, Meghan, Rogalskı, Emily , Salloway, Stephen, Sha, Sharon J., Turner, Raymond Scott, Wingo, Thomas S., Wolk, David A., Carrillo, Maria C., Rabinovici, Gil D., Dickerson, Bradford C., Dage, Jeffrey L., Apostolova, Liana G., Carrillo, María C. , Rabinovici, Gil D. , Joie, Renaud La , Polsinelli, Angelina J. , La Joie, Renaud , Rabinovici, Gil D , Hammers, Dustin B , Eloyan, Ani , Taurone, Alexander, Thangarajah, Maryanne, Foroud, Tatiana , Gao, Sujuan , Beckett, Laurel , Touroutoglou, Alexandra , Vemuri, Prashanthi , Zetterberg, Henrik , Blennow, Kaj , Kostadinova, Ralitsa, Aisen, Paul , Nudelman, Kelly , Kirby, Kala, Atri, Alireza , Clark, David, Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Johnson, Erik C. B. , Jones, David T. , Masdeu, Joseph C , Mendez, Mario F. , Womack, Kyle , Musiek, Erik , Onyike, Chiadi U. , Riddle, Meghan , Salloway, Stephen , Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S , Wolk, David A. , Dickerson, Bradford Clark , Dage, Jeffrey L. , Apostolova, Liana G.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | May 4, 2026 | Volume: 18 | Issue: 2 | Pages: No page available

10.1002/dad2.70342 | PMID 42088846 Get It

Abstract INTRODUCTION : Despite expanding use of plasma biomarkers for Alzheimer's disease (AD), minimal examination has been undertaken in early‐onset AD (EOAD). Prior analyses assessed criterion and convergent validity of common plasma biomarkers in a well‐characterized sample with sporadic EOAD. METHODS : Plasma amyloid beta (Aβ) 42/40, tau phosphorylated at threonine 231 (p‐tau231), glial fibrillary acidic protein (GFAP), and neurofilament light change (NfL) levels were obtained for 189 EOAD, 52 early‐onset non‐AD (EOnonAD), and 83 cognitively normal (CN) participants. Diagnostic group differences, convergence with imaging biomarkers, and the capacity to predict specific cognitive domains were investigated. RESULTS : After controlling for cognitive status, EOAD participants exhibited more pathologic levels of Aβ42/40, p‐tau231, and GFAP relative to EOnonAD participants. However, NfL displayed the greatest sensitivity to non‐amnestic cognitive impairment across the sample. DISCUSSION : These results establish criterion and convergent validity of plasma biomarkers in sporadic EOAD and highlight complementary roles that AD‐specific and non‐specific plasma markers may play across the course of AD care.
Abstract TU205: The Effect of Physical Activity on the Gut Microbiome in Prediabetes: Results from a Randomized Controlled Trial
Demmer, Ryan, Pope, Zachary, Avenido, Francis Ryan, Mitchell, Nathan, Hubbard, Paige Richmond, Johnson, Stephen, McDonough, DJ, Rydell, Sarah, Johnson, Abigail, Pereira, Mark, Demmer, Ryan T. , Pope, Zachary , Mitchell, Nathan R , Hubbard, Paige F. Richmond, Johnson, Stephen, Sharma, Shweta , Rydell, Sarah A.

Mayo Clinic

Circulation | April 30, 2026 | Volume: 153 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.153.suppl_1.tu205 Get It

Objective: To test the effect of physical activity on the gut microbiome and circulating short chain fatty acids among sedentary overweight/obese adults with prediabetes. We hypothesized that randomization to increased physical activity would result in gut microbiome changes. Methods: \We randomized 77 adults with prediabetes and a sedentary lifestyle into one of two groups: 1) Intervention Group: Invited to engage in home-based moderate intensity walking 3x/week for 30 minutes/session in weeks 1-4 and for 45 minutes/session during weeks 5-8 of the 8-week intervention; or 2) Control Group: Maintained habitual physical activity levels. We performed metagenomic sequencing from stool collected at baseline, week 4, and week 8, with short-chain fatty acids (SCFA) measured from serum collected at baseline and week 8. Taxonomic and functional profiling were performed on the metagenomic reads; alpha diversity metrics were subsequently derived. Linear regression assessed the difference in change between the intervention and control groups for alpha-diversity and SCFA levels. Results: We screened 1,533 participants for eligibility and consented 132. Of these, 87 entered the run-in phase and 77 were randomized. Participants were 51.4±8.9 years old, 87.7% female, and 74% non-Hispanic White. Mean fasting glucose was 103.3±13.2 while mean BMI was 34.4±5.7. In comparison to the control group, the intervention group experienced decreased alpha diversity as characterized by Shannon, Richness, and Faith’s diversity indices by week 8 of the intervention (P<0.05). SCFA levels trended towards improvement in the intervention group, but the results were not statistically significant. Functional analysis of KEGG ontologies revealed themes consistent with a microbiome with enhanced metabolic activity and host-relevant metabolic signaling (Figure). Conclusions: Randomization to a walking intervention resulted in modest gut microbiome changes among adults with overweight/obesity and prediabetes.
Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability
Mukherjee, Sovanlal , Antony, Ajith , Trivedi, Kamaxi H. , Karbhari, Aashna , Bhinder, Khurram Khaliq , Truty, Mark, Johnson, Matthew P. , Goenka, Ajit H. , Patnam, Nandakumar G. , Chari, Suresh T , Goenka, Ajit Harishkumar , Zarrintan, Armin , Fletcher, Joel G. , Truty, Mark J. , Chari, Suresh T.

Mayo Clinic

Gut | April 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: gutjnl-2025-337266

10.1136/gutjnl-2025-337266 | PMID 42049489 Get It

Background Failure of conventional imaging to detect pancreatic ductal adenocarcinoma (PDA) at its visually occult pre-diagnostic stage is a primary barrier to improving its otherwise poor rate of survival. Objective To develop and validate the Radiomics-based Early Detection MODel (REDMOD), an AI framework to identify subvisual radiomic signatures of pre-diagnostic PDA on standard-of-care CT. Designs REDMOD was trained on a multi-institutional cohort (n=969; 156 pre-diagnostic, 813 control) and tested on an independent set (n=493; 63 pre-diagnostic, 430 control), simulating a low prevalence (~1:6) early detection paradigm. The fully automated framework couples AI-driven segmentation with a heterogeneous ensemble architecture trained on a 40-feature radiomic signature derived from Synthetic Minority Over-sampling Technique (SMOTE)-balanced data. A tunable Youden Index-optimised classification threshold enables performance calibration without retraining. Validation included direct comparison with radiologists, longitudinal test–retest analysis and external specificity validation across two independent cohorts (n=539 and n=80). Results On an independent test set (n=493), REDMOD identified occult PDA (AUC 0.82; 73.0% sensitivity) at a median 475-day lead time. This represented nearly twofold higher sensitivity than radiologists (38.9%; p<0.001), which grew to nearly threefold (68.0% vs 23.0%) at >24 months lead time. REDMOD showed strong longitudinal stability (90–92% concordance) and generalisable specificity across multi-institutional (81.3%; n=539) and public (87.5%; n=80) datasets. Mechanistic analyses confirmed predictive power derived principally from multi-scale wavelet-filtered textural features (90% of selected signature), which outperformed unfiltered features (AUC 0.82 vs 0.74; p=0.007) in capturing subvisual architectural disruptions. Conclusions REDMOD is an automated, mechanistically grounded, longitudinally stable, externally validated AI that surpasses radiologists for PDA detection at its visually occult pre-diagnostic stage. These attributes position it for prospective validation in high-risk cohorts, a necessary step towards shifting the paradigm from late-stage symptomatic diagnosis to proactive pre-clinical interception.
INTERMITTENT HYPOXIA TRAINING IN HEART FAILURE: A PILOT STUDY
Sabapathy, Surendran , Shrama, Pramod, Roberts, Llion, O'Connor, Fergus, Johnson, Bruce, Morris, Norman, Roberts, Llion Arwyn , O’Connor, Fergus K.

Mayo Clinic

Journal of Clinical Exercise Physiology | April 28, 2026 | Volume: 15 | Issue: s2 | Pages: 228

10.31189/2165-7629-15-s2.228 Get It

Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy
Eliashiv, Dawn , Rao, Vikram R. , Jobst, Barbara C. , Szaflarski, Jerzy P. , Rolston, John D., Kaye, Lesley , Bullinger, Katie L. , Dugan, Patricia , Burdette, David E. , Peters, Angela , Sheikh, Atif, Haas, Kevin F., Mnatsakanyan, Lilit , Bensalem‐Owen, Meriem, Study, for the RNS System PAS, Doherty, Michael J., Razavi, Babak, Fisher, Tiffany , Modur, Pradeep N., Constantino, Tawnya, Salanova, Vicenta , Taraschenko, Olga , Rivera‐Cruz, Angélica , Balabanov, Antoaneta, Aboumatar, Sami, Fried, Itzhak , Drees, Cornelia , Shin, Hae Won, Jaisani, Zeenat , Maciver, Stephanie , Patra, Sanjay , Chang, Edward F. , Gwinn, Ryder, Stoub, Travis , Crabtree, Tami , Seale, Cairn G. , McFadden, Sharon C. , Norman, Jacob F. , Johnson, Lise, Elisevich, Kort, Peng, Emory, Mazumder, Rajashi, Jennings, Tara, Esparza, Melissa Johnston, Harid, Nitish, Farooque, Pue , Hirsch, Lawrence, Gerrard, Jason, Wabulya, Angela , Riley, Kristen, Pati, Sandipan, Johnson, Jessica, Kirchoffer, Kaitlyn, Bamps, Yvan , Rolston, John D. , Rolston, John D , Kaye, Lesley C , Ganguly, Taneeta Mindy , Bullinger, Katie , Dugan, Patricia C , Burdette, David E , Peters, Angela Y , Sheikh, Atif , Haas, Kevin F , Nair, Dileep R , Mnatsakanyan, Lilit , Quraishi, Imran H , Bensalem-Owen, Meriem K , Doherty, Michael J , Razavi, Babak , Fisher, Tiffany L. , Skidmore, Christopher , Modur, Pradeep N , Constantino, Tawnya M , Cole, Andrew J , Taraschenko, Olga , Rivera-Cruz, Angelica , Wheless, James W , Tandon, Nitin , Balabanov, Antoaneta , Aboumatar, Sami , Fried, Itzhak , Drees, Cornelia , Shin, Hae Won , Jaisani, Zeenat , MacIver, Stephanie E , Patra, Sanjay E , Chang, Edward F , Willie, Jon T , Gwinn, Ryder , Stoub, Travis , Stern, John M , Crabtree, Tami , McFadden, Sharon C , Norman, Jacob F , Johnson, Lise , Morrell, Martha J , Jobst, Barbara , Rao, Vikram R , Ganguly, Taneeta M. , Nair, Dileep , Skidmore, Christopher , Cole, Andrew J. , Wheless, James W. , Tandon, Nitin , Gwinn, Ryder P. , Stern, John M. , Morrell, Martha J. , Pellinen, Jacob , Herlopian, Aline , Sivaraju, Adithya , Damisah, Eyiyemisi C. , Gerrard, Jason L. , Bentley, J. Nicole , Pati, Sandipan Bankim Behari

Mayo Clinic

Neurology | April 24, 2026 | Volume: 106 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000214875 | PMID 42030518 Get It

Ivosidenib in predominantly recurrent IDH1-mutant glioma: A single-institution experience
Rael, Sofia , Neth, Bryan J. , Johnson, Derek, Sosa, Santiago Martinez, Mathis, Ganiru O, Uhm, Joon H. , Ruff, Michael W. , Kizilbash, Sani H, Campian, Jian L, Giannini, Caterina, Schultz, Sydney Ellen, Jaeckle, Kurt, Sherman, Wendy, Mrugala, Maciej M, Galloway, Taylor, Breen, William G. , Lehrer, Eric J. , Jenkins, RB , Sener, Ugur, Johnson, Derek R. , Sener, Uğur , Lachance, Daniel H , Johnson, Derek R , Lachance, Daniel , Jaeckle, Kurt A , Galloway, Taylor M, Breen, Will , Sener, Ugur , Neth, Byran J. , Sosa, Santiago Martinez , Lachance, Daniel Honore , Kizilbash, Sani H. , Campian, Jian , Giannini, Caterina , Parney, Ian F. , Burns, Terry C. , Schultz, Sydney E, Jaeckle, Kurt A. , Mrugala, Maciej , Galloway, Taylor , Drucker, Kristen , Jenkins, Robert B.

Mayo Clinic

Neuro-Oncology Practice | April 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/nop/npag037 | PMID 42750887 Get It

Abstract Background Isocitrate dehydrogenase (IDH)-mutant gliomas are infiltrative tumors with limited treatment options at recurrence. Early studies suggest IDH inhibition has therapeutic activity. We evaluated clinical outcomes associated with IDH-1 inhibitor ivosidenib in recurrent IDH-1-mutant gliomas and molecular predictors of response. Methods We retrospectively analyzed adults treated with ivosidenib from January 2021 to August 2025 with predominantly recurrent, pretreated CNS WHO grade 2-4 astrocytoma IDH-mutant or grade 2-3 oligodendroglioma, IDH-mutant and 1p/19q codeleted. Prior anticancer treatments, toxicities, enhancement status at ivosidenib initiation, and genomic alterations were collected. The primary endpoint was progression-free survival (PFS); secondary analyses evaluated associations between PFS, genomic complexity, and CDKN2A/B homozygous deletion. Results Ninety-two adults, median age 43, were included: 61 astrocytomas and 31 oligodendrogliomas, mostly grade 2. Before ivosidenib, 69 had surgery, 64 chemotherapy, and 64 radiation. Median time from diagnosis to ivosidenib was 4.8 years, with median of two prior progressions. Median treatment duration was 5.8 months. Median PFS was 15.2, 4.6, and 2.1 months for astrocytoma grades 2-4, 14.0 and 6.9 months for oligodendroglioma grades 2-3. Increasing genomic complexity was associated with shorter PFS in univariate analysis. Patients without CDKN2A/B homozygous deletion had median PFS of 19.2 months. Two patients with homozygous deletion had median PFS of 0.6 months. Conclusions In this retrospective analysis of predominantly recurrent IDH-1-mutant glioma, ivosidenib was associated with longer PFS in lower-grade, non-enhancing tumors that received little or no prior anticancer treatment and less complex genomic profiles. These findings support a context-dependent benefit of IDH inhibition in recurrent disease.
Toward a Diagnostic Template for Acquired Apraxia of Speech: Insights From an Academy of Neurologic Communication Disorders Review
King, Charlotte , Bislick, Lauren , Nealon, Kate , Johnson, Rachel, Utianski, Rene L. , Wambaugh, Julie , Haley, Katarina L. , Wambaugh, Julie L. , Johnson, Rachel K. , Johnson, Rachel , Utianski, Rene L , Haley, Katarina L

Mayo Clinic

American Journal of Speech-Language Pathology | April 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1044/2026_ajslp-25-00433 | PMID 42017773 Get It

Purpose: Significant variation is observed in diagnostic assessments for individuals with acquired apraxia of speech (AOS). The lack of consistency across research related to AOS impacts the comparison of intervention outcomes. This extends to diagnostic criteria, assessment, and the inclusion of patient demographics. This viewpoint examines outcomes related to the consistency in diagnostic tool use and collection of demographic information and introduces a template to support researchers and clinicians conducting diagnostic evaluations. Materials include guidelines for a thorough case history, current diagnostic characteristics, and diagnostic assessment tools available for describing AOS. The template illustrates how such materials can be structured and applied in research and clinical practice. Method: The recommendations provided in this viewpoint are part of a recent systematic review about AOS treatment outcomes. Trained raters extracted data from a comprehensive literature search from 1951 to April 2024 using a consensus protocol. Results: Of the 92 studies included in data extraction, demographic information such as age, gender, etiology, and months post-onset was commonly reported, and information about race and ethnicity (described in 15% of studies), socioeconomic status (0%), current/previous occupation (8%), language history (10%), and education (59%) was described less frequently. Reported diagnostic characteristics varied across studies, reflecting differences in using discriminatory versus nondiscriminatory features. Concomitant diagnoses, such as aphasia severity (37%) and presence of dysarthria (32%), were not consistently reported or described. Conclusion: A template with specific criteria and assessments can support research replication, raise awareness of diagnostic strategies, and offer a structured framework for investigators and clinicians. Supplemental Material: https://doi.org/10.23641/asha.32012346
Complex dynamics between internalized HIV stigma, depression, and anxiety with panic among people with HIV
Crane, H M, Fredericksen, Rob J. , Whitney, Bridget M. , Cachay, Edward, Mayer, Kenneth H., Christopoulos, Katerina, Moore, R, Keruly, Jeanne , Chander, Geetanjali , Johnson, Mallory O. , Saag, Michael S., Crawford, Timothy, Falade, Oluwaseun, Kitahata, Mari M., Bamford, Laura, Yendewa, George A , Delaney, J A C, Drumright, Lydia N. , Crane, Heidi M. , Cachay, Edward R. , Mayer, Kenneth Hugh , Christopoulos, Katerina A. , Napravnik, Sonia , Saag, Michael S. , Neilands, Torsten B. , Crawford, Timothy, Kitahata, Mari M. , Yendewa, George A. , Delaney, Joseph A. , Frost, Simon D. W.

Mayo Clinic

AIDS | April 21, 2026 | Volume: 40 | Issue: 9 | Pages: 1355-1364

10.1097/qad.0000000000004525 | PMID 42013436 Get It

Background: Previous studies suggest that internalized HIV stigma (IHS) results in HIV viral nonsuppression via directly increasing depression, which then reduces adherence leading to nonsuppression; however, the dynamics between IHS and mental health are likely more complex. We sought to better understand IHS-mental health dynamics using data from a longitudinal clinical cohort of people with HIV (PWH) receiving healthcare across 10 US primary care clinics. Methods: Among 8,506 PWH who had ≥2 timepoints in which IHS, depression, and anxiety were measured, we examined changes over time in both two-state (i.e., impact of IHS on depression or anxiety and vice versa) and four-state combinations of depression-IHS (i.e., no depression or IHS, depression/no IHS, no depression/IHS, both depression/IHS) and anxiety-IHS. Transition probabilities between states and factors influencing transitions were identified using multistate Markov models. Results: The impact of IHS on the transition rates of mental health measures (i.e., depression, anxiety) and vice versa were almost the same, suggesting that each influences the other. Over 50% of PWH remained in the same IHS-depression or IHS-anxiety state. PWH with IHS had almost twice the rate of transitioning from no depression/anxiety to having depression/anxiety compared to PWH without IHS; with similar results for the depression or anxiety with no IHS to reporting IHS transition. Conclusions: We demonstrate that IHS and mental health dynamics are more complex than previously suspected and that the associations are bidirectional, which has implications for both future analyses and optimal management of these conditions among PWH.